223 related articles for article (PubMed ID: 30328119)
1. Utility of CD30, Ki-67, and p53 in assisting with the diagnosis of mycosis fungoides with large cell transformation.
Raghavan SS; Hong EK; Kim YH; Kim J
J Cutan Pathol; 2019 Jan; 46(1):33-43. PubMed ID: 30328119
[TBL] [Abstract][Full Text] [Related]
2. Retrospective Analysis of Prognostic Factors in 187 Cases of Transformed Mycosis Fungoides.
Talpur R; Sui D; Gangar P; Dabaja BS; Duvic M
Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):49-56. PubMed ID: 26702474
[TBL] [Abstract][Full Text] [Related]
3. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.
Kim YH; Prince HM; Whittaker S; Horwitz SM; Duvic M; Bechter O; Sanches JA; Stadler R; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown LC; Ortiz-Romero PL; Akilov OE; Trotman J; Taylor K; Weichenthal M; Walewski J; Fisher D; McNeeley M; Gru AA; Brown L; Palanca-Wessels MC; Lisano J; Onsum M; Bunn V; Little M; Trepicchio WL; Dummer R
Eur J Cancer; 2021 May; 148():411-421. PubMed ID: 33794441
[TBL] [Abstract][Full Text] [Related]
4. Spatially Resolved Transcriptomes of CD30+-Transformed Mycosis Fungoides and Cutaneous Anaplastic Large-Cell Lymphoma.
Choi ME; Lee MY; Won CH; Chang SE; Lee MW; Lee WJ
J Invest Dermatol; 2024 Feb; 144(2):331-340.e2. PubMed ID: 37544586
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
Nguyen GH; Olson LC; Magro CM
Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940
[TBL] [Abstract][Full Text] [Related]
6. Disease characteristics, prognosis, and response to therapy in patients with large-cell transformed mycosis fungoides: A single-center retrospective study.
O'Donnell M; Zaya R; Correia E; Krishnasamy S; Sahu J; Shi W; Cha J; Alpdogan SO; Porcu P; Nikbakht N
J Am Acad Dermatol; 2022 Jun; 86(6):1285-1292. PubMed ID: 34273458
[TBL] [Abstract][Full Text] [Related]
7. The expression of CXCR3 and CD30 in mycosis fungoides.
Nikoo A
Arch Iran Med; 2012 Mar; 15(3):146-50. PubMed ID: 22369302
[TBL] [Abstract][Full Text] [Related]
8. Mycosis fungoides with CD30-positive cells in the epidermis.
Wu H; Telang GH; Lessin SR; Vonderheid EC
Am J Dermatopathol; 2000 Jun; 22(3):212-6. PubMed ID: 10871063
[TBL] [Abstract][Full Text] [Related]
9. CD30 expression and proliferative fraction in nontransformed mycosis fungoides.
Edinger JT; Clark BZ; Pucevich BE; Geskin LJ; Swerdlow SH
Am J Surg Pathol; 2009 Dec; 33(12):1860-8. PubMed ID: 19898220
[TBL] [Abstract][Full Text] [Related]
10. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
11. Mycosis fungoides with large cell transformation (CD30+) and B-cell chronic lymphocytic leukemia.
Petković M; Ilić I; Jurakić Tončić R; Radman-Livaja I; Čeović R
Acta Dermatovenerol Croat; 2023 Dec; 31(4):223-224. PubMed ID: 38651850
[TBL] [Abstract][Full Text] [Related]
12. Correlations between clinical and pathological features in 17 cases of mycosis fungoides before and after transformation.
Bittencourt AL; Oliveira PD; Carvalho-Andrade A; Araújo I
Int J Dermatol; 2015 Sep; 54(9):e327-31. PubMed ID: 26147565
[TBL] [Abstract][Full Text] [Related]
13. Assessment of diagnostic criteria between primary cutaneous anaplastic large-cell lymphoma and CD30-rich transformed mycosis fungoides; a study of 66 cases.
Fauconneau A; Pham-Ledard A; Cappellen D; Frison E; Prochazkova-Carlotti M; Parrens M; Dalle S; Joly P; Viraben R; Franck F; Ingen-Housz-Oro S; Giacchero D; Jullié ML; Vergier B; Merlio JP; Beylot-Barry M
Br J Dermatol; 2015 Jun; 172(6):1547-1554. PubMed ID: 25645336
[TBL] [Abstract][Full Text] [Related]
14. Large-cell transformation of mycosis fungoides-differential diagnosis with implications for clinical management: a consensus statement of the US Cutaneous Lymphoma Consortium.
Kadin ME; Hughey LC; Wood GS
J Am Acad Dermatol; 2014 Feb; 70(2):374-6. PubMed ID: 24438952
[No Abstract] [Full Text] [Related]
15. Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors.
Pulitzer M; Myskowski PL; Horwitz SM; Querfeld C; Connolly B; Li J; Murali R
Pathology; 2014 Dec; 46(7):610-6. PubMed ID: 25393251
[TBL] [Abstract][Full Text] [Related]
16. Transformation of mycosis fungoides: T-cell receptor beta gene analysis demonstrates a common clonal origin for plaque-type mycosis fungoides and CD30+ large-cell lymphoma.
Wood GS; Bahler DW; Hoppe RT; Warnke RA; Sklar JL; Levy R
J Invest Dermatol; 1993 Sep; 101(3):296-300. PubMed ID: 8396607
[TBL] [Abstract][Full Text] [Related]
17. Mycosis fungoides in plaque stage with pronounced eosinophilic infiltration, folliculotropism, and concomitant invasive squamous cell carcinoma.
Terada T
Int J Clin Exp Pathol; 2013; 6(4):749-56. PubMed ID: 23573323
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in 105 Japanese cases of mycosis fungoides and Sézary syndrome: clusterin expression as a novel prognostic factor.
Tobisawa S; Honma M; Ishida-Yamamoto A; Saijo Y; Iizuka H
J Dermatol Sci; 2013 Sep; 71(3):160-6. PubMed ID: 23702390
[TBL] [Abstract][Full Text] [Related]
19. Recognizing large-cell transformation of mycosis fungoides.
Herrmann JL; Hughey LC
J Am Acad Dermatol; 2012 Oct; 67(4):665-72. PubMed ID: 22261416
[TBL] [Abstract][Full Text] [Related]
20. Expression of SATB1, MTI/II and Ki-67 in Mycosis Fungoides.
Jankowska-Konsur A; Kobierzycki C; Reich A; Grzegrzolka J; Bieniek A; Dziegiel P
Anticancer Res; 2016 Jan; 36(1):189-97. PubMed ID: 26722043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
